Letter to shareholders — Rights Issue

Sep 25, 2018
Posted in: Investor updates

Home » Letter to shareholders — Rights Issue

Letter to shareholders — Rights Issue

Sep 25, 2018
Posted in: Investor updates

Imagion Biosystems has lodged the announcement “Pro-Rata Non-Renounceable Rights Issue” with the Australian Securities Exchange.
View the announcement “Pro-Rata Non-Renounceable Rights Issue.”

Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer

February 19, 2025

MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce

Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority

November 14, 2024

Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority

Successful Placement of A$3M

October 10, 2024

Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Letter to shareholders — Rights Issue

Letter to shareholders — Rights Issue

Related Articles

Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer

Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority

Successful Placement of A$3M

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list